Baker BROS. Advisors LP Has $51.48 Million Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Baker BROS. Advisors LP lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 55.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,308,011 shares of the company's stock after purchasing an additional 464,936 shares during the period. CRISPR Therapeutics accounts for about 0.5% of Baker BROS. Advisors LP's investment portfolio, making the stock its 23rd biggest holding. Baker BROS. Advisors LP owned approximately 1.53% of CRISPR Therapeutics worth $51,483,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Highline Wealth Partners LLC acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter worth about $39,000. Western Pacific Wealth Management LP raised its stake in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after acquiring an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in CRISPR Therapeutics in the 3rd quarter worth approximately $40,000. Spire Wealth Management lifted its holdings in CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company's stock worth $78,000 after purchasing an additional 1,482 shares during the last quarter. Finally, MCF Advisors LLC bought a new stake in CRISPR Therapeutics during the fourth quarter worth approximately $80,000. 69.20% of the stock is currently owned by institutional investors.

Insider Buying and Selling at CRISPR Therapeutics

In other news, COO Julianne Bruno sold 1,198 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the sale, the chief operating officer now owns 8,263 shares in the company, valued at approximately $350,516.46. This represents a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,381 shares of company stock worth $1,608,243 over the last ninety days. Corporate insiders own 4.30% of the company's stock.

CRISPR Therapeutics Trading Down 0.6 %

CRSP stock traded down $0.20 during trading on Friday, hitting $35.94. The company had a trading volume of 1,209,934 shares, compared to its average volume of 1,667,554. The company has a fifty day moving average price of $38.31 and a two-hundred day moving average price of $42.85. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $67.88. The company has a market cap of $3.10 billion, a P/E ratio of -8.22 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. The business's revenue was up 71.6% on a year-over-year basis. During the same quarter last year, the company posted ($1.43) earnings per share. On average, analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Ratings Changes

CRSP has been the subject of a number of analyst reports. Needham & Company LLC reduced their price objective on shares of CRISPR Therapeutics from $84.00 to $81.00 and set a "buy" rating for the company in a research note on Wednesday. Chardan Capital cut their target price on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a research report on Wednesday. TD Cowen upgraded shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price target for the company in a report on Wednesday, February 12th. Morgan Stanley lifted their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an "underweight" rating in a research note on Friday, February 14th. Finally, Truist Financial increased their target price on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $71.58.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.